Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca; BeyondSpring Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Epizyme, Inc.; Exelixis, Inc.; GlaxoSmithKline; Ipsen Biopharmaceuticals, Inc; Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company; Jazz Pharmaceuticals, Inc.; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Seattle Genetics, Inc.; and Taiho Oncology, Inc.

Clinical Vignette Series: 38th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

Release Date: January 28, 2021
Expiration Date: January 28, 2022

Activity Overview

In Clinical Vignette Series: 38th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow®, oncology thought leaders address clinical challenges faced by community oncologists like you, and offer their insight and commentary on the clinical application of new data and advances. This interactive, online activity features a series of case-based vignettes, self-reflection questions, and brief audio-video clips in which the program faculty share their approaches and answer other related questions. This activity touches on established and emerging standards of care in chronic lymphocytic leukemia and multiple myeloma, as well as cancers of the breast, lung, kidney, and liver. It is based on content presented at the 2020 CFS® meeting, an annual gathering with a longstanding history of providing education, guidance, perspectives, and solutions to practicing oncologists. Delivering state-of-the-art cancer care requires incorporation of new clinical advances and data into practice. Across all cancer types, improvements in patient outcomes are being driven by novel approaches in testing, systemic therapy, targeted therapy and immunotherapies, and combination strategies. This online activity provides an unparalleled opportunity to learn about these new methods for optimizing and personalizing care for your patients with cancer.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; BeyondSpring Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Epizyme, Inc.; Exelixis, Inc.; GlaxoSmithKline; Ipsen Biopharmaceuticals, Inc; Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company; Jazz Pharmaceuticals, Inc.; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Seattle Genetics, Inc.; and Taiho Oncology, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists involved in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline recent advances in biomarker testing across multiple tumor type for personalizing therapy
  • Discuss strategies to integrate recent evidence from clinical trials utilizing immunotherapy, targeted therapy, and/or chemotherapy across multiple tumor type into clinical practice
  • Review practice changing evidence presented at major conferences and that informs clinical decision making with respect to diagnosis or management across solid tumors as well hematologic cancers
  • Apply best practices and multidisciplinary strategies for monitoring, mitigating, and managing treatment-related toxicities in patients being treated for cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Richard R. Furman, MD
Richard R. Furman, MD
Morton Coleman, M.D. Distinguished Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant Research Support: Acerta Pharma, AstraZeneca, Janssen Pharmaceutical Companies, TG Therapeutics; Consultant: AbbVie, Acerta Pharma, AstraZeneca, BeiGene, Genentech, Janssen Pharmaceutical Companies, Pharmacyclics, Loxo Oncology, OncoTracker, Sunesis Pharmaceuticals, Verastem Oncology, TG Therapeutics; Shareholder: Janssen Pharmaceutical Companies; Other: Data Safety Monitoring Board: Incyte.

Mark G. Kris, MD
Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AstraZeneca, Pfizer, and Daiichi Sankyo.

Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP
Professor and Chair, Department of Hematology & Medical Oncology
Emory School of Medicine
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: Consultant: Merck, Novartis, Onyx, Millennium, Bristol Myers Squibb, Sanofi, Celgene, Janssen.

Heather L. McArthur, MD, MPH
Heather L. McArthur, MD, MPH
Medical Director, Breast Oncology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: Grant Research Support: Bristol Myers Squibb, MedImmune, Ziopharm Oncology, Merck, Eli Lilly and Company; Consultant: Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Pfizer, Puma Biotechnology, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Peregrine Pharmaceuticals, Calithera Biosciences, DaiichiSankyo Company, Seattle Genetics, AstraZeneca and TapImmune.

Sandip P. Patel, MD
Sandip P. Patel, MD
Associate Professor, UCSD
Co-Leader, Experimental Therapeutics
Deputy Director, San Diego Center for Precision Immunotherapy
Interim Director, Clinical Trials Office
UC San Diego
La Jolla, CA

Disclosures: Grant Research Support: Bristol Myers Squibb, Eli Lilly and Company, Incyte, AstraZeneca/MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery, Fate Therapeutics, Genocea, Iovance Biotherapeutics; Consultant: AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Illumina, Rakuten, Paradigm, Tempus.

Lewis R. Roberts, MB, ChB, PhD
Lewis R. Roberts, MB, ChB, PhD
Consultant, Division of Gastroenterology and Hepatology, Department of Internal Medicine
Professor of Medicine
Mayo Clinic
Rochester, MN

Disclosures: Grant Research Support: Ariad Pharmaceuticals, Bayer, BTG International, Gilead Sciences, Glycotest, Target PharmaSolutions, Wako Diagnostics, RedHill Biopharma, Exact Sciences; Consultant: AstraZeneca Pharmaceuticals LP; Other: Exact Sciences Advisory Board, QED Therapeutics Advisory Board, Tavec Advisory Board, Grail Advisory Board, Gilead Sciences Advisory Board.

Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research Support: Pfizer, Merck, Novartis, Ely Lilly & Company, Genentech, OBI, Odonate, Daiichi-Sankyo, Eisai Co, Seattle Genetics, MacroGenics, Sermonix, and Immunomedics; Consultant: Samsung and Puma (limited consulting); Other: Travel: Daiichi-Sankyo, Mylan, Pfizer, Merck, AstraZeneca, Novartis, and MacroGenics.

Che-Kai Tsao, MD
Che-Kai Tsao, MD
Associate Professor
The Mount Sinai Hospital
New York, NY

Disclosures: Grant Research Support: Exelixis; Shareholder: Gilead Sciences.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By